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left main coronary artery lesions showed similar outcomes with re-
gard to death, MI, and TVR.
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BACKGROUND This study sought to compare the clinical perfor-
mances of zotarolimus-eluting stents(ZES) and everolimus-eluting
stents (EES) for multi-vessel coronary artery disease.
METHODS From August 2006 to December 2013, a total of 1989
consecutive patients with multi-vessel coronary artery disease un-
derwent percutaneous coronary intervention (PCI) with ZES (N ¼
1,106) or EES (N ¼ 973) implantation in Asan Medical Center. Primary
outcome was deﬁned as the composite of death, myocardial infarc-
tion, or target vessel revascularization (MACE: major adverse cardio-
vascular event) at 3 years.
RESULTS The adjusted-risk of MACE (hazard ratio[HR], 0.88; 95%
conﬁdence interval[CI] 0.66-1.16, P¼0.36) did not differ between pa-
tient who received ZES and EES implantation at 3 years. The adjusted
risk of death (HR, 0.78; 95% CI, 0.54-1.15, P¼0.21), the composite of
death or myocardial infarction (HR, 0.79; 95% CI, 0.55-1.12, P¼0.18),
and target vessel revascularization (HR, 0.78; 95% CI, 0.69-1.62,
P¼0.79) were also similar between ZES and EES group. The 3-year
cumulative incidence of deﬁnite or probable stent thrombosis was
0.5% and 0.4% in ZES and EES group, respectively.
CONCLUSIONS The clinical performance of ZES and EES were not
signiﬁcantly different for patients with multi-vessel coronary artery
disease.
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BACKGROUND Little is known about the clinical follow-up after
sirolimus-eluting stent (SES) implantation and about the effect of SES
implantation in in-stent restenosis (ISR) lesion more than ﬁve years.
We aimed to compare clinical outcomes up to 10 years after SES im-
plantation in de novo lesion and ISR lesion.
METHODS A series of 392 patients underwent the ﬁrst SES im-
plantation between November 2002 and December 2004, whose
clinical outcomes were investigated. There were 253 patients for de
novo lesion and 139 patients for ISR lesion. We evaluated the out-
comes after SES implantation and clinical information was obtained
either from a review of the hospital records or by telephone in-
terviews with the patients, family members, or primary care
physicians.
RESULTS Mean follow up period was 10.0 years. Cumulative inci-
dence of major cardiac events (MACE) and target-lesion revasculari-
zation in ISR group were signiﬁcantly higher than that in de novo
group through 10 years (56.1% vs. 38.7%; p ¼ 0.01, and 41.3% vs.
20.6%; p ¼ 0.004, respectively) and the difference of the MACE and
TLR rate in two groups increased in this period. Cumulative incidence
of myocardial infarction (MI) and stent thrombosis (ST) between 2
groups were not signiﬁcantly different (13.0% vs. 7.9%; p ¼ 0.1, and
5.0% vs. 2.4%; p ¼ 0.15, respectively).
CONCLUSIONS The incidence of MACE and TLR after the SES im-
plantation in ISR lesion was signiﬁcantly higher than that in de novo
lesion and the difference of the TLR rate between in two lesions
became more clear through 10 years, although the incidence of MI and
ST had no signiﬁcant difference in 2 groups.
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